Association between metformin medication, genetic variation and prostate cancer risk
- 1 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Prostate Cancer and Prostatic Diseases
- Vol. 24 (1), 96-105
- https://doi.org/10.1038/s41391-020-0238-y
Abstract
Background The relationship between metformin use and prostate cancer risk remains controversial. Genetic variation in metformin metabolism pathways appears to modify metformin glycemic control and the protective association with some cancers. However, no studies to date have examined this pharmacogenetic interaction and prostate cancer chemoprevention. Methods Clinical data and germline DNA were collected from our prostate biopsy database between 1996 and 2014. In addition to a genome-wide association study (GWAS), 27 single nucleotide polymorphisms (SNPs) implicated in metformin metabolism were included on a custom SNP array. Associations between metformin use and risk of high-grade (Grade Group >= 2) and overall prostate cancer were explored using a case-control design. Interaction between the candidate/GWAS SNPs and the metformin-cancer association was explored using a case-only design. Results Among 3481 men, 132 (4%) were taking metformin at diagnosis. Metformin users were older, more likely non-Caucasian, and had higher body mass index, Gleason score, and number of positive cores. Overall, 2061 (59%) were diagnosed with prostate cancer, of which 922 (45%) were high-grade. After adjusting for baseline characteristics, metformin use was associated with higher risk of high-grade prostate cancer (OR = 1.76, 95% CI 1.1-2.9, p = 0.02) and overall prostate cancer (OR = 1.77, 95% CI 1.1-2.9, p = 0.03). None of the 27 candidate SNPs in metformin metabolic pathways had significant interaction with the metformin-cancer association. Among the GWAS SNPs, one SNP (rs149137006) had genome-wide significant interaction with metformin for high-grade prostate cancer, and another, rs115071742, for overall prostate cancer. They were intronic and intergenic SNPs, respectively, with largely uncharacterized roles in prostate cancer chemoprevention. Conclusions In our cohort, metformin use was associated with increased risk of being diagnosed with prostate cancer. While SNPs involved in metformin metabolism did not have modifying effects on the association with disease risk, one intronic and one intergenic SNP from the GWAS study did, and these require further study.This publication has 48 references indexed in Scilit:
- A Common 5′-UTR Variant in MATE2-K Is Associated With Poor Response to MetforminClinical Pharmacology & Therapeutics, 2011
- Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association studyNature Genetics, 2011
- Understanding the benefit of metformin use in cancer treatmentBMC Medicine, 2011
- Common variants near ATM are associated with glycemic response to metformin in type 2 diabetesNature Genetics, 2011
- A Comparison of Sample Size and Power in Case-Only Association Studies of Gene-Environment InteractionAmerican Journal of Epidemiology, 2010
- Status of PI3K inhibition and biomarker development in cancer therapeuticsAnnals of Oncology, 2009
- Metformin use and prostate cancer in Caucasian men: results from a population-based case–control studyCancer Causes & Control, 2009
- Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL ConsortiumCancer Epidemiology, Biomarkers & Prevention, 2008
- Effect of Genetic Variation in the Organic Cation Transporter 1, OCT1, on Metformin PharmacokineticsClinical Pharmacology & Therapeutics, 2007
- High levels of untreated distress and fatigue in cancer patientsBritish Journal of Cancer, 2004